Cynata Therapeutics Ltd
OTC:CYYNF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (137.9), the stock would be worth $0.08 (63% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 373.6 | $0.22 |
0%
|
| 3-Year Average | 137.9 | $0.08 |
-63%
|
| 5-Year Average | 137.9 | $0.08 |
-63%
|
| Industry Average | 131.4 | $0.08 |
-65%
|
| Country Average | 4.1 | $0 |
-99%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$70m
|
/ |
Jan 2026
AU$203.4k
|
= |
|
|
$70m
|
/ |
Jun 2026
AU$2.1m
|
= |
|
|
$70m
|
/ |
Jun 2027
AU$2.3m
|
= |
|
|
$70m
|
/ |
Jun 2028
AU$2.5m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Cynata Therapeutics Ltd
OTC:CYYNF
|
76m USD | 373.6 | -9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 5.9 | 86.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 4.9 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.4 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 5 | 15.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 11.4 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.7 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 4.1 |
| 70th Percentile | 11.8 |
| Max | 1 679 509.2 |
Other Multiples
Cynata Therapeutics Ltd
Glance View
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, which the Company has branded as Cymerus. The Cymerus technology facilitates the manufacture of MSCs from a single donor and a single donation, which enables the development of therapeutic stem cell products. The firm's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). Its technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Company’s lead product candidate, CYP-001, which has met all clinical endpoints and demonstrated safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase I trial.
